Determination of cancer antigen 125 in ovarian carcinoma

Indian Journal of Clinical Biochemistry

Volumn 18, Issue 2, 2003, Pages 27-33

  Thakur, Vinita ^a   Anand, A K ^a   Mukherjee, U ^a   Ghosh, D ^a  

^a Batra Hospital India   (India)

Author keywords

Epithelial tumour; Ovarian Carcinoma; Serum CA125

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; EPITHELIUM TUMOR; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LIFE EXPECTANCY; OVARY CARCINOMA; PATIENT MONITORING; RADIOLOGY; SERODIAGNOSIS;

EID: 0042433132     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02867364     Document Type: Article

References (16)

1. Rustin, G.J.S., Nelstrop, A., Stilwel, J. and Lambert, H.E. (1992). Savings obtained by CA125 measurements during therapy for ovarian carcinoma. Eur. J. Cancer. 28, 79-82.
2. Levin, P.T., Knapp, R.C., Malkasian, G., Whitney, C.W., Besek, J.S. and Bast, R.C. (1987). CA 125 for the monitoring of ovarian carcinoma during pretreatment. Obstet. Gynecol. 69,223-227.
3. Vergote, I.B., Bormen, O.P. and Abeler, V.M. (1987). Elevation of serum CA 125 levels in the monitoring of ovarian cancer. Am. Obstet. Gynecol. 157, 88-92
4. Redman, C.W.E., Black ledge, G.R., Kelly, K., Powell, S., Buxton, E.J. and Lueslay, D.M. (1990).Can early serum CA 125 response predict outcome in epithelial ovarian cancer? Eur. J. Cancer 26, 593-596.
5. Vander Burg, M.E.L., Laumes, F.B., Van Patten, W.L.J. and Stoter, G. (1988). Ovarian cancer, the prognostic value of the serum half life of CA 125 during induction chemotherapy. Gynecol. Oncol. 30, 307-312
6. Rustin, G.J.S., Gennengs, J.N., Nelstrop, A.E., Covarrubias, H., Lambert, H.E. and Bagshawe, K.D. (1987). Use of CA 125 to predict survival of patients with ovarian carcinoma. J. Clin. Oncol. 7, 1667-1671.
7. Fisken, J., Leonard, R.C.F., Stewart, F., Beattie, G.J., Sturgeon, C., Aspinall, L. and Roulston, J.E. (1993). The prediagnostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br. J. Cancer 68,140-145.
8. Welander, C.E. (1992). What do CA125 and other antigen tell us about ovarian cancer biology? Acta Obstet. Gynecol. Scand. 155, 85-93.
9. Kenemans, P., Verstraetem, A.A., Van kamp, G.J. and Hinger, J. (1994). CA 125 in the management of ovarian carcinoma (Abs 562) Ann, Oncol. 5, 112.
10. Bast, R.C., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B. and Knalp, R.C. (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337.
11. Munstedt, K., Krisch, M., Sachsse, S. and Vahrson, H. (1997). Serum CA125 levels and survival in advanced ovarian cancer. Arch. Gynecol. Veslet. 259, 117-123.
12. Kudoh, K., Kikuchi, Y., Kite, T., Tode, T., Takano, M., Hirata, J., Mano, Y., Yamamoto, K. and Nagata, I. (1999). Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynae. Obstet. Invest. 47, 52-57.
13. Serum Cancer antigen 125 (CA125). Mayo Medical Labo Communique, 12(5), Rochester MN 1987.
14. Bast, R.C., Klug, T.L., John, E.S., Niloff, J.M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, C.T., Parker, L., Zurawski, V.R. and Knapp, R.C. (1983). A radioimmuno assay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887.
15. Vander Burg, M.E.L., Myles, J.D., Hoskins, P.J. et al (1993). CA125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. Eur. J. Cancer 29A, 133 (Suppl. 6, Abstract 723).
16. Kudelka, A.P., Tresukosol, D., Edwards, C. L., Feedman, R.S., Levenback, C., Chantarawiroj, P., Leon, C.G.D., Kim, E.E., Madden, T., Wallin, H., Hord, M., Verschraegen, C., Raber, M. and Kavanagh, J.J. (1996). Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14 (5), 1552-1557.